Analysts at Barclays Maintain their Past ‘Equal-Weight’ rating on Shares PTC Therapeutics (NASDAQ:PTCT), Set a $43 Price Objective

August 9, 2018 - By Matthew Richard

PTC Therapeutics, Inc. (NASDAQ:PTCT) Logo

Investors sentiment increased to 1.26 in 2018 Q1. Its up 0.28, from 0.98 in 2017Q4. It is positive, as 16 investors sold PTC Therapeutics, Inc. shares while 37 reduced holdings. 36 funds opened positions while 31 raised stakes. 38.49 million shares or 8.57% more from 35.45 million shares in 2017Q4 were reported.

Ubs Asset Americas reported 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Great Point Ptnrs Limited Liability Corporation holds 0.01% or 1.54 million shares in its portfolio. State Street Corporation has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Alliancebernstein Lp holds 0% or 49,350 shares. Renaissance Technologies Lc holds 0.01% or 219,200 shares. The Maryland-based Proshare Advsrs has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Bluecrest Ltd holds 0.03% or 30,192 shares in its portfolio. Deutsche Savings Bank Ag reported 455,944 shares stake. Pub Employees Retirement Association Of Colorado has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Royal Comml Bank Of Canada holds 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT) or 200 shares. State Board Of Administration Of Florida Retirement Systems has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). 272,012 are held by Mak Cap One Ltd Llc. South Dakota Investment Council has 0.06% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). 24,299 were reported by Tekla Cap Mgmt.

Since June 1, 2018, it had 0 buys, and 2 selling transactions for $1.15 million activity. Shares for $966,240 were sold by Almstead Neil Gregory.

PTC Therapeutics (NASDAQ:PTCT) Rating Reaffirmed

PTC Therapeutics (NASDAQ:PTCT) just had their share rating of a ‘Equal-Weight’ issued by research analysts at Barclays, who now has a $43 PT on the $2.01 billion market cap company or a 0.05 % upside potential. This key information was released in an analyst note on 8 August.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. PTC Therapeutics has $50 highest and $24 lowest target. $36.80’s average target is -14.38% below currents $42.98 stock price. PTC Therapeutics had 12 analyst reports since February 22, 2018 according to SRatingsIntel. RBC Capital Markets upgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday, June 18 to “Outperform” rating. The company was maintained on Wednesday, March 7 by Barclays Capital. The firm earned “Hold” rating on Wednesday, March 7 by RBC Capital Markets. Bank of America maintained it with “Underperform” rating and $31 target in Tuesday, July 31 report. The stock has “Outperform” rating by William Blair on Monday, June 18. On Tuesday, July 24 the stock rating was maintained by Citigroup with “Buy”. The firm earned “Hold” rating on Wednesday, April 18 by Cowen & Co. Citigroup maintained the shares of PTCT in report on Thursday, February 22 with “Buy” rating. The firm earned “Equal-Weight” rating on Wednesday, August 8 by Barclays Capital. On Wednesday, June 20 the stock rating was upgraded by Barclays Capital to “Equal-Weight”.

The stock increased 5.55% or $2.26 during the last trading session, reaching $42.98. About 510,472 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 144.83% since August 9, 2017 and is uptrending. It has outperformed by 132.26% the S&P500.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $2.01 billion. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 07/19 (PTCT) (CE) (ISRG) Higher; (SKX) (ZYNE) (FTD) Lower (more…)” on July 19, 2018, also Seekingalpha.com with their article: “PTC Therapeutics to acquire Agilis Biotherapeutics for $200M; shares up 8.5%” published on July 19, 2018, Benzinga.com published: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” on August 07, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Seekingalpha.com and their article: “PTC Therapeutics Inc, (PTCT) CEO Stu Peltz on Q2 2018 Results – Earnings Call Transcript” published on August 08, 2018 as well as Nasdaq.com‘s news article titled: “Options Traders Expect Huge Moves in PTC Therapeutics (PTCT) Stock” with publication date: July 11, 2018.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.